HomeENGLISH MAGAZINEMCL-1 to the rescue: BH domains set 3 breast cancer from death

MCL-1 to the rescue: BH domains set 3 breast cancer from death

A protein frequently found in high levels in breast cancer cells helps tumors to survive and grow, and could be targeted with a new type of drug that is already being tested for other cancers, new research reveals. The new study confirms that a protein called MCL-1 helps breast cancer cells survive, by hindering cells’ natural ability to die through a process called apoptosis, and proves that breast cancer tumors in fact rely on this protein to help them grow more aggressively, by blocking this natural cellular self-destruct function. Apoptosis is a natural process by which unwanted, harmful or damaged cells are removed from our bodies and plays an important part in our growth and development. Apoptosis can also play a key role in preventing cancer; however, cancer cells will often evolve to avoid this process. Cells use a family of apoptosis-controlling proteins called the BCL-2 family. Some of them suppress celle death (like Bcl-2, Bcl-XL ed MCL-1 itself), while others induce apoptosis (e.g. BAX, BAD, Bak, Bcl-XS, etc.).

Inhibitors against Bcl-2 have been developed, like the anticancer drug venetoclax, that is also already employed against breast cancer. Current breast cancer treatments target a range of proteins, but this study could be an important step towards targeting MCL-1 as a way to treat people with breast cancer and developing urgently needed new treatments for the disease. The study has also discovered that breast cancer stem cells, which are thought to be responsible for the disease spreading and becoming resistant to treatments, are especially dependent on MCL-1 for growth and survival. Excitingly, the study suggests a new type of drug called BH3 mimetics, which target the MCL-1 protein, could be used to ‘kick-start’ apoptosis in breast cancer cells to help treat people with breast cancer, and slow the growth of tumors. BH3 mimetcs are fragments of Bcl2 family members comprising their BH2 domain (a ligand segment for the BH3 domain), or drugs modeled on computer programs to resemble the BH3 domain.

This new research, published in Cell Death & Differentiation, the team showed that MCL-1 is critical for the growth and survival of breast cancer in lab mice models. When MCL-1 was removed from existing breast tumors in mice, it led to tumors shrinking. The results suggest that targeting MCL-1 with drugs could work as a treatment strategy for breast cancer. The team then tested whether BH3 mimetic drugs, targeting the MCL-1 protein, could stop the growth of breast cancer in mice. BH3 mimetics are already undergoing clinical trials for some blood cancers. While further testing is needed, this new study presents a strong case to test this emerging new therapy in breast cancer too. The results showed that the growth of tumors was significantly slowed down and suggests that with further testing, BH3 mimetic drugs have the potential to treat people affected by breast cancer. Moreover, in the absence of the BAX and Bak proteins – which are essential for apoptosis – targeting MCL-1 did not slow the growth of tumors.

Professor Stephen Tait of the Institute of Cancer Sciences, commented: “Our study further highlights the importance of MCL-1 protein in breast cancer. The next steps will be to determine the effectiveness of MCL-1 targeting drugs, that are in clinical development, to treat breast cancer in combination with existing therapies. It’s hugely exciting that this study could confirm the role that the MCL-1 protein plays in allowing breast cancer cells to survive and grow. With this understanding we can now explore targeting the protein with drugs that are already being tested for treating other types of cancer. With around 55,000 women being diagnosed with breast cancer every year in the UK, we urgently need to find new ways to treat people and prevent deaths from this devastating disease. As such, while further research is needed, we hope this study leads to new and effective treatments being available for people affected by breast cancer. We’re hugely proud to have funded this exciting discovery, especially at a time when we are all too aware of the profound effects the COVID-19 pandemic has already had on our world-class research”.

  • Edited by Dr. Gianfrancesco Cormaci, PhD, specialist in Clinical Biochemistry.

Scientific references

Campbell KJ et al. Cell Death Differ. 2021 Mar 31.

Floros KV et al. Cell Death Dis. 2021 Feb; 12(2):179. 

Cruz-Gordillo P et al. Sci Signal. 2020; 13(658):eabb9820. 

Dott. Gianfrancesco Cormaci
- Laurea in Medicina e Chirurgia nel 1998 (MD Degree in 1998) - Specialista in Biochimica Clinica nel 2002 (Clinical Biochemistry residency in 2002) - Dottorato in Neurobiologia nel 2006 (Neurobiology PhD in 2006) - Ha soggiornato negli Stati Uniti, Baltimora (MD) come ricercatore alle dipendenze del National Institute on Drug Abuse (NIDA/NIH) e poi alla Johns Hopkins University, dal 2004 al 2008. - Dal 2009 si occupa di Medicina personalizzata. - Guardia medica presso strutture private dal 2010 - Detentore di due brevetti sulla preparazione di prodotti gluten-free a partire da regolare farina di frumento immunologicamente neutralizzata (owner of patents concerning the production of bakery gluten-free products, starting from regular wheat flour). - Responsabile del reparto Ricerca e Sviluppo per la società CoFood s.r.l. (leader of the R&D for the partnership CoFood s.r.l.) - Autore di un libro riguardante la salute e l'alimentazione, con approfondimenti su come questa condizioni tutti i sistemi corporei. - Autore di articoli su informazione medica e salute sui siti web salutesicilia.com, medicomunicare.it e in lingua inglese sul sito www.medicomunicare.com
- Advertisment -